Sino Biopharmaceutical Dirección

Dirección controles de criterios 2/4

El CEO de Sino Biopharmaceutical's es Eric S. Y. Tse, nombrado en Jul 2022, tiene una permanencia de 1.75 años. posee directamente un 22.09% de las acciones de la empresa, con un valor de $1.31B. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 9 años, respectivamente.

Información clave

Eric S. Y. Tse

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.8yrs
Participación del CEO	22.1%
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	9.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Eric S. Y. Tse en comparación con los beneficios de Sino Biopharmaceutical?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥2b
Dec 31 2022	n/a	n/a	CN¥2b
Sep 30 2022	n/a	n/a	CN¥5b
Jun 30 2022	n/a	n/a	CN¥8b
Mar 31 2022	n/a	n/a	CN¥14b
Dec 31 2021	CN¥23m	CN¥6m	CN¥15b
Sep 30 2021	n/a	n/a	CN¥12b
Jun 30 2021	n/a	n/a	CN¥10b
Mar 31 2021	n/a	n/a	CN¥4b
Dec 31 2020	CN¥25m	CN¥7m	CN¥3b
Sep 30 2020	n/a	n/a	CN¥2b
Jun 30 2020	n/a	n/a	CN¥3b
Mar 31 2020	n/a	n/a	CN¥3b
Dec 31 2019	CN¥6m	CN¥870k	CN¥3b

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Eric S. Y. es razonable en comparación con empresas de tamaño similar en el mercado US.

Compensación vs. Ingresos: La compensación de Eric S. Y. ha sido consistente con los resultados de la empresa en el último año.

CEO

Eric S. Y. Tse (27 yo)

1.8yrs

Permanencia

CN¥23,092,000

Compensación

Mr. Eric S. Y. Tse serves as an Executive Director at Sino Biopharmaceutical Limited since October 23, 2019 and serves as its Chief Executive Officer since July 28, 2022. Mr. Tse joined Sino Biopharmaceuti...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Y. Y. Tse	Executive Chairwoman of the Board	8.9yrs	CN¥39.66m	0.033% CN¥ 2.2m
Cheung Ling Cheng	Executive Vice Chairwoman of the Board	7.1yrs	CN¥35.18m	16.19% CN¥ 1.1b
Mingqin Li	Senior VP & Executive Director	no data	CN¥1.20m	sin datos
Zhoushan Tian	Executive Director	no data	CN¥1.87m	sin datos
Hsin Tse	Senior VP & Executive Director	no data	CN¥6.03m	1.95% CN¥ 131.8m
Eric S. Y. Tse	CEO & Executive Director	1.8yrs	CN¥23.09m	22.11% CN¥ 1.5b
Ping Tse	Founder & Senior Executive Vice Chairman	3.8yrs	CN¥41.92m	9.12% CN¥ 616.5m
Chun Ling Li	Chief Financial Officer	1.3yrs	sin datos	sin datos
Sean Chen	Chief Strategy Officer	1.3yrs	sin datos	sin datos
Orphanides George	Chief Scientific Advisor of invoX	1.3yrs	sin datos	sin datos
Chau Ling Yu	Assistant VP & Financial Controller	no data	sin datos	sin datos
Toogood Ben	CEO of invoX & Head of Globalization	1.3yrs	sin datos	sin datos

1.3yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SBHM.Y no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Y. Y. Tse	Executive Chairwoman of the Board	8.9yrs	CN¥39.66m	0.033% CN¥ 2.2m
Cheung Ling Cheng	Executive Vice Chairwoman of the Board	7.1yrs	CN¥35.18m	16.19% CN¥ 1.1b
Mingqin Li	Senior VP & Executive Director	9.1yrs	CN¥1.20m	sin datos
Zhoushan Tian	Executive Director	9.1yrs	CN¥1.87m	sin datos
Hsin Tse	Senior VP & Executive Director	no data	CN¥6.03m	1.95% CN¥ 131.8m
Eric S. Y. Tse	CEO & Executive Director	4.6yrs	CN¥23.09m	22.11% CN¥ 1.5b
Ping Tse	Founder & Senior Executive Vice Chairman	3.8yrs	CN¥41.92m	9.12% CN¥ 616.5m
Zhengfei Lu	Independent Non-Executive Director	18.5yrs	CN¥340.00k	sin datos
Dakui Li	Independent Non-Executive Director	19.7yrs	CN¥352.00k	sin datos
Lu Fu Zhang	Independent Non-Executive Director	9.1yrs	CN¥340.00k	sin datos
Hong Lu	Independent Non-Executive Director	9.1yrs	CN¥320.00k	sin datos
Kwok Tung Li	Independent Non-Executive Director	3.4yrs	CN¥340.00k	0.00039% CN¥ 26.4k

9.1yrs

Permanencia media

59.5yo

Promedio de edad

Junta con experiencia: La junta directiva de SBHM.Y se considera experimentada (9 años de antigüedad promedio).

Sino Biopharmaceutical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 06, 2022

Sino Biopharmaceutical Limited Appoints Li Kwok Tung Donald as an Independent Non-Executive Director and a Member of the Audit Committee and Nomination Committee

Sino Biopharmaceutical Limited Announces Management Changes

Recent updates

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024

Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"

Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet

Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart

Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion.

Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553)

Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain

Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722

Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038

An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million.

Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug

An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million.

An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million.

Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023

Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023

Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms

Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine

Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection)

Sino Biopharmaceutical Limited Announces Clinical Trial Application of Innovative Medicine "Tqb2103 (Claudin18.2 ADC)" Accepted by Center for Drug Evaluation

Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innovative Drug Tqb2450 Injection in Combination with Anlotinib Hydrochloride Capsules for the Indication of First-Line Treatment of Small Cell Lung Cancer

Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Clinical Trial of "Tqg203"

Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the period ended 30 June 2022, Payable on 28 September 2022

Sino Biopharmaceutical Limited to Report First Half, 2022 Results on Aug 23, 2022

Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022

Sino Biopharmaceutical Limited Announces Application for Marketing of Category 1 Anti-Tumor Innovative Drug TQ-B3101 Capsule

Sino Biopharmaceutical Limited Announces Approval of Category 1 Innovative Drug TQC2938 Injection for Clinical Trial

Sino Biopharmaceutical Submits Application for Marketing of the Category I Anti-Tumor Innovative Drug "TQ-B3139"

Sino Biopharmaceutical Limited's Category I Anti-Tumor Innovative Drug "TQB2930" Obtained Approval for Clinical Trial

Sino Biopharmaceutical Limited Announces Anlotinib Hydrochloride Capsules Obtains Approval for the Fifth Indication

Sino Biopharmaceutical Limited Announces Innovative Drug "TQ-B3525" Was Included in the List of Breakthrough Therapy Drugs by CDE

Sino Biopharmaceutical Limited Announces That Application for Clinical Trial of "TQC2938" Injection, A Category I New Drug Self-Developed by the Group, Has Been Submitted to and Accepted by the National Medical Products Administration of China

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 06, 2022

Sino Biopharmaceutical Limited Announces Category I Anti-Tumour Innovative Medicine FHND5071 Obtained Approval for Clinical Trial

Sino Biopharmaceutical Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

Sino Biopharmaceutical Limited Announces Approval of "Adalimumab Solution for Injection" for Marketing

Sino Biopharmaceutical Limited Announces Sitagliptin Phosphate and Metformin Hydrochloride Sustained-Release Tablets Obtained Drug Registration Certificate Granted by National Medical Products Administration

Sino Biopharmaceutical Limited's TCR1672 Obtains Approval for Clinical Trial

Akeso, Inc. and Sino Biopharmaceutical Limited Announces Penpulimab Monoclonal Antibody Marketing Approval in China

Sino Biopharmaceutical Limited Announces "Dexmedetomidine Hydrochloride Injection" Obtains Drug Registration Certificate

Sino Biopharmaceutical Limited Announces That the Phase Iii Clinical Trial Results of "Anlotinib Hydrochloride Capsules

Sino Biopharmaceutical Limited Announces "Tolvaptan Tablets" Obtains Drug Registration Certificate

Sino Biopharmaceutical Limited Announces "Sunitinib Malate Capsules" Obtains Drug Registration Certificate

Sino Biopharmaceutical Limited Declares Dividend for the Three Months Ended 31 March, 2021, Payable on 12 July, 2021

Sino Biopharmaceutical Limited Announces "Decitabine for Injection" Passes Consistency Evaluation

Sino Biopharmaceutical Limited to Report Fiscal Year 2020 Results on Mar 23, 2021

Akeso, Inc. and Sino Biopharmaceutical Limited Announce the Interim Analysis of the Phase III Clinical Trial of Penpulimab

Sino Biopharmaceutical Limited Announces Alfacalcidol Soft Capsule Obtains the Notice of Approval of Supplemental Application on Pharmaceutical Product Issued by the National Medical Products Administration of the People's Republic of China

Sino Biopharmaceutical Limited Announces "Esomeprazole Magnesium Enteric-Coated Capsules" Obtains Drug Registration Certificate

Sino Biopharmaceutical Limited Announces Passing of Consistency Evaluation for Bortezomib for Injection

Akeso, Inc. and Sino Biopharmaceutical Limited Announces Latest Study of Penpulimab Monoclonal Antibody (PD-1) in Combination with Anlotinib for 1L Advanced Hepatocellular Carcinoma

Sino Biopharmaceutical Limited Announces Passing of Consistency Evaluation for "Linezolid and Glucose Injection"

Sino Biopharmaceutical Limited Obtains Drug Registration Certificate for Afatinib Dimaleate Tablets

Sino Biopharmaceutical Limited Appoints Li Kwok Tung Donald as an Independent Non-Executive Director and a Member of the Audit Committee and Nomination Committee

Sino Biopharmaceutical Limited's Digestive System Medicine Pantoprazole Sodium for Injection Obtains the Notice of Approval of Supplemental Applications Issued by the National Medical Products Administration of the People's Republic of China

Sino Biopharmaceutical Limited Announces Pomalidomide Capsules Obtains Drug Registration Certificate

Sino Biopharmaceutical Limited to Report Q3, 2020 Results on Nov 30, 2020

Sino Biopharmaceutical Limited Announces Completion of Enrollment in Phase Iii Clinical Trial in Combination with Chemotherapy for 1L Metastatic Squamous Nsclc with Penpulimab

Sino Biopharmaceutical Limited Announces Management Changes

Sino Biopharmaceutical Limited to Report First Half, 2020 Results on Aug 28, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo